Apyx Medical (APYX) Common Equity (2010 - 2026)

Apyx Medical (APYX) has reported Common Equity for 17 consecutive years, with $11.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 48.74% year-over-year to $11.1 million; the trailing twelve-month figure through Jun 2026 stood at $11.1 million (up 48.74% YoY), and the FY2025 full-year result was $14.8 million, up 3.46% from the prior year.
• Common Equity slipped to $11.1 million in Q2 2026 per APYX's latest filing, from $13.1 million in the prior quarter.
• Across five years, Common Equity topped out at $49.8 million in Q1 2022 and bottomed at $6.1 million in Q3 2025.
• Historically, Common Equity has averaged $24.1 million across 5 years, with a median of $17.7 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Common Equity tumbled 66.66% in 2024, then surged 48.74% in 2026.
• Over 5 years, Common Equity stood at $37.8 million in 2022, then retreated by 28.76% to $26.9 million in 2023, then slumped by 46.75% to $14.3 million in 2024, then advanced by 3.46% to $14.8 million in 2025, then decreased by 25.22% to $11.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $11.1 million, $13.1 million, and $14.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.